Neill R Graff-Radford

List of Publications by Year
in descending order

373 papers	30,416 citations	6592 79 h-index	7496 151 g-index
412 all docs	412 docs citations	412 times ranked	28105 citing authors

#	Article	IF	Citations
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
2	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	1.9	0
3	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
4	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.4	4
5	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
6	Clinical Deep Phenotyping of ABCA7 Mutation Carriers. Neurology: Genetics, 2022, 8, e655.	0.9	4
7	Plugâ€andâ€play advanced magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2022, 87, 2613-2620.	1.9	5
8	2021 marks a new era for Alzheimer's therapeutics. Lancet Neurology, The, 2022, 21, 3-4.	4.9	10
9	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	4.5	15
10	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
11	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
12	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
13	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
14	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
15	Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans. EBioMedicine, 2022, , 103929.	2.7	2
16	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
17	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
18	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6

#	Article	IF	Citations
19	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
20	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
21	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
22	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
23	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
24	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
25	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.4	27
26	Plasma Biomarkers of Alzheimerâ€™s Disease in African Americans. Journal of Alzheimer's Disease, 2021, 79, 323-334.	1.2	11
27	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
28	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
29	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
30	Prevalence and Trends in Management of Idiopathic Normal Pressure Hydrocephalus in the United States: Insights from the National Inpatient Sample. World Neurosurgery, 2021, 145, e38-e52.	0.7	10
31	Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations. NMR in Biomedicine, 2021, 34, e4325.	1.6	9
32	Acrossâ€•vendor standardization of semiâ€•LASER for singleâ€•voxel MRS at 3T. NMR in Biomedicine, 2021, 34, e4218.	1.6	43
33	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
34	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
35	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5
36	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	3.9	5

#	Article	IF	Citations
37	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
38	Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. Journal of Alzheimer's Disease, 2021, 80, 397-405.	1.2	4
39	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	3.7	66
40	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
41	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
42	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology, 2021, 96, e2546-e2557.	1.5	38
43	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 2311.	5.8	44
44	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
45	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
46	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
47	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
48	Long-term ovarian hormone deprivation alters functional connectivity, brain neurochemical profile and white matter integrity in the Tg2576 amyloid mouse model of Alzheimer's disease. Neurobiology of Aging, 2021, 102, 139-150.	1.5	7
49	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
50	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
51	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
52	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	4.9	26
53	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. Parkinsonism and Related Disorders, 2021, 89, 155-161.	1.1	12
54	Apolipoprotein E regulates lipid metabolism and Î±-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	3.9	25

#	Article	IF	Citations
55	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
56	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
57	APOE3 Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
58	Response to â€œLetter to the editor concerning "High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus" by Naylor et al. (Clinical Neurology and Neurosurgery) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2021, 208, 106820.	0.6	0
59	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
60	A Neurologist's Practical Approach to Cognitive Impairment. Seminars in Neurology, 2021, 41, 686-698.	0.5	0
61	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
62	Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.4	0
63	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
64	Risk factors of neurovascular ageing in women. Journal of Neuroendocrinology, 2020, 32, e12777.	1.2	12
65	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
66	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. JAMA Neurology, 2020, 77, 225.	4.5	50
67	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
68	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
69	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
70	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
71	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
72	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25

#	Article	IF	Citations
73	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
74	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
75	Predictors of adverse outcomes and cost after surgical management for idiopathic normal pressure hydrocephalus: Analyses from a national database. Clinical Neurology and Neurosurgery, 2020, 197, 106178.	0.6	10
76	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
77	High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus. Clinical Neurology and Neurosurgery, 2020, 197, 106099.	0.6	6
78	Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy. Menopause, 2020, 27, 872-878.	0.8	8
79	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimerâ€™s disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	5.8	172
80	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
81	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35
82	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	1.4	5
83	Neuroimaging biomarkers in prodromal DLB. Alzheimer's and Dementia, 2020, 16, e042856.	0.4	0
84	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
85	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
86	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
87	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
88	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31
89	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
90	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47

#	Article	IF	Citations
91	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	15.2	351
92	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. Frontiers in Neurology, 2020, 11, 80.	1.1	13
93	Confirmation of ¹²³I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
94	Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. Nature Metabolism, 2020, 2, 688-702.	5.1	64
95	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
96	Our Efforts in Understanding Normal Pressure Hydrocephalus: Learning from the 100 Most Cited Articles by Bibliometric Analysis. World Neurosurgery, 2020, 137, 429-434.e13.	0.7	7
97	Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study. Menopause, 2020, 27, 305-310.	0.8	9
98	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
99	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
100	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.4	13
101	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
102	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
103	Reply to â€œAmyloid Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damageâ€• Annals of Neurology, 2020, 87, 988-989.	2.8	0
104	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. Brain Pathology, 2020, 30, 766-778.	2.1	19
105	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
106	Incorporating Sex as a Biological Variable into Clinical and Translational Research Training. Journal of Women's Health, 2020, 29, 865-867.	1.5	5
107	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
108	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17

#	Article	IF	Citations
109	Reproductive history and progressive multiple sclerosis risk in women. Brain Communications, 2020, 2, fcaa185.	1.5	28
110	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
111	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
112	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
113	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
114	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Annals of Clinical and Translational Neurology, 2019, 6, 1782-1796.	1.7	20
115	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R912-R920.	0.9	15
116	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
117	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
118	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
119	Association of white matter microstructural integrity with cognition and dementia. Neurobiology of Aging, 2019, 83, 63-72.	1.5	32
120	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
121	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
122	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
123	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
124	Disproportionately enlarged subarachnoid-space hydrocephalus (DESH) in normal pressure hydrocephalus misinterpreted as atrophy: autopsy and radiological evidence. Neurocase, 2019, 25, 151-155.	0.2	8
125	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
126	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62

#	Article	IF	Citations
127	Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?. Sleep, 2019, 42, .	0.6	9
128	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
129	Reply to letter: Basis of cingulate island sign may differ in dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 761-762.	2.2	2
130	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	1.7	18
131	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	3.7	36
132	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
133	A proteomic signature for dementia with Lewy bodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 270-276.	1.2	18
134	Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magnetic Resonance in Medicine, 2019, 82, 527-550.	1.9	280
135	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
136	Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multiâ€Ethnic (FLAME) cohort. Alzheimer's and Dementia, 2019, 15, 635-643.	0.4	29
137	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
138	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
139	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
140	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
141	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
142	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97
143	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
144	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53

#	Article	IF	Citations
145	Development of ¹ H MRS biomarkers for tracking early predementia Alzheimer disease. Neurology, 2019, 92, 209-210.	1.5	7
146	¹⁸Fâ€Aâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
147	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
148	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
149	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
150	Normal Pressure Hydrocephalus. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 165-186.	0.4	24
151	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
152	Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. Journal of Psychiatry and Brain Science, 2019, 4, .	0.3	3
153	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
154	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
155	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
156	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
157	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
158	AutoVOI: realâ€time automatic prescription of volumeâ€ofâ€interest for single voxel spectroscopy. Magnetic Resonance in Medicine, 2018, 80, 1787-1798.	1.9	32
159	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
160	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
161	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
162	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. Parkinsonism and Related Disorders, 2018, 50, 99-103.	1.1	22

#	Article	IF	Citations
163	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
164	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
165	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
166	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
167	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
168	Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magnetic Resonance in Medicine, 2018, 79, 1241-1250.	1.9	38
169	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
170	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
171	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
172	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.4	116
173	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
174	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
175	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
176	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. Maturitas, 2018, 117, 64-77.	1.0	10
177	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	5.8	100
178	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
179	F1â€01â€04: DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P200.	0.4	0
180	Sex and age interact to determine clinicopathologic differences in Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 873-885.	3.9	69

#	Article	IF	Citations
181	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	4.3	87
182	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
183	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Molecular Neurodegeneration, 2018, 13, 37.	4.4	54
184	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	2.8	25
185	Multimodal imaging in RBD â€" present and future. Nature Reviews Neurology, 2018, 14, 574-576.	4.9	1
186	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
187	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.5	37
188	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's and Dementia, 2018, 14, 1171-1183.	0.4	468
189	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
190	Prior Menopausal Hormone Treatments And Association of Peripheral Markers of Neurovascular Unit Integrity And Î²â€amyloid in The Brains of Menopausal Women. FASEB Journal, 2018, 32, lb449.	0.2	0
191	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
192	ABCA7 loss-of-function variants, expression, and neurologic disease risk. Neurology: Genetics, 2017, 3, e126.	0.9	26
193	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
194	Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimerâ€™s Disease Genes in African Americans Identifies Novel PSEN Variants. Journal of Alzheimer's Disease, 2017, 56, 1215-1222.	1.2	4
195	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
196	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
197	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
198	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.4	45

#	Article	IF	Citations
199	APOE Î¼4/Î¼4 diminishes neurotrophic function of human iPSC-derived astrocytes. Human Molecular Genetics, 2017, 26, 2690-2700.	1.4	162
200	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	1.6	42
201	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
202	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
203	African American exome sequencing identifies potential risk variants at Alzheimer disease loci. Neurology: Genetics, 2017, 3, e141.	0.9	25
204	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
205	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
206	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. Journal of Neurology, 2017, 264, 938-945.	1.8	24
207	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	0.7	93
208	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	2.2	46
209	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.4	48
210	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
211	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
212	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
213	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
214	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
215	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
216	Midlife and Lateâ€Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	1.6	54

#	Article	IF	Citations
217	Multipleâ€dose ponezumab for mildâ€toâ€moderate Alzheimer's disease: Safety and efficacy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 339-347.	1.8	43
218	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
219	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	3.8	493
220	[P3â€“356]: VENTRICULOMEGALY IS A BIOMARKER OF GAIT AND COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1092.	0.4	1
221	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
222	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
223	<scp>S</scp>tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Movement Disorders, 2017, 32, 115-123.	2.2	48
224	Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2017, 13, 119-129.	0.4	87
225	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
226	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
227	Regional T₁ relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magnetic Resonance in Medicine, 2017, 77, 774-778.	1.9	17
228	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
229	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
230	[O1â€“02â€“05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P187.	0.4	1
231	[O2â€“07â€“06]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPAUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P570.	0.4	2
232	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
233	African American Dementia Caregiver Problem Inventory: Descriptive analysis and initial psychometric evaluation.. Rehabilitation Psychology, 2017, 62, 25-35.	0.7	8
234	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€C. Movement Disorders, 2016, 31, 653-662.	2.2	60

#	Article	IF	Citations
235	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23
236	Human whole genome genotype and transcriptome data for Alzheimerâ€™s and other neurodegenerative diseases. Scientific Data, 2016, 3, 160089.	2.4	361
237	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	1.2	30
238	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 5-14.	1.2	17
239	P1â€337: African American Brain Autopsies from The National Alzheimerâ€™s Coordinating Center. Alzheimer's and Dementia, 2016, 12, P557.	0.4	0
240	O4â€01â€01: Pattern of AVâ€1451 Uptake in Dementia with Lewy Bodies and its Association with Amyloidâ€Beta Deposition. Alzheimer's and Dementia, 2016, 12, P329.	0.4	0
241	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
242	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34.	1.2	44
243	MR spectroscopy, APOE genotype, and evolving Î²-amyloid pathology. Neurology, 2016, 86, 1750-1751.	1.5	2
244	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S70-6.	0.9	63
245	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
246	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
247	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
248	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
249	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	1.0	3
250	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
251	A blood screening test for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 83-90.	1.2	54
252	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70

#	Article	IF	Citations
253	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurology, 2016, 73, 1231.	4.5	49
254	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
255	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	5.8	68
256	Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e301.	3.1	78
257	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
258	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
259	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
260	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
261	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
262	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
263	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
264	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	4.9	87
265	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
266	Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimerâ€™s disease brains. Molecular Neurodegeneration, 2016, 11, 72.	4.4	55
267	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
268	Case Studies Illustrating Focal Alzheimerâ€™s, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia. Neurologic Clinics, 2016, 34, 699-716.	0.8	3
269	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
270	Neuropathologic differences by race from the National Alzheimer's Coordinating Center. Alzheimer's and Dementia, 2016, 12, 669-677.	0.4	75

#	Article	IF	Citations
271	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
272	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139, 1005-1007.	3.7	6
273	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
274	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
275	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23
276	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.4	42
277	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
278	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
279	Genetic variants associated with susceptibility to psychosis inÂlate-onset Alzheimerâ€™s disease families. Neurobiology of Aging, 2015, 36, 3116.e9-3116.e16.	1.5	14
280	IC-02-05: Hippocampal volumes predict risk of dementia with lewy bodies in mild cognitive impairment. , 2015, 11, P7-P8.		0
281	Jump from Pre-mutation to Pathologic Expansion in C9orf72. American Journal of Human Genetics, 2015, 96, 962-970.	2.6	50
282	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	4.5	59
283	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.4	205
284	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.5	51
285	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
286	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	3.9	235
287	O3-01-03: Effects of hormone therapy on brain structure in recently postmenopausal women: A randomized controlled trial. , 2015, 11, P217-P218.		0
288	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19

#	Article	IF	Citations
289	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
290	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
291	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
292	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
293	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
294	TREM2 is associated with increased risk for Alzheimerâ€™s disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	4.4	130
295	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
296	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
297	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27
298	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
299	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
300	Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurology: Genetics, 2015, 1, e15.	0.9	64
301	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
302	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
303	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	4.5	39
304	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
305	Late-onset Alzheimerâ€™s risk variants in memory decline, incident mild cognitive impairment, and Alzheimerâ€™s disease. Neurobiology of Aging, 2015, 36, 60-67.	1.5	90
306	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24

#	Article	IF	Citations
307	Fractional Anisotropy of the Fornix and Hippocampal Atrophy in AlzheimerÃ¢â‚¬â„¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 316.	1.7	63
308	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
309	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
310	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
311	Past hormone therapy in older women. Neurology, 2014, 82, 380-381.	1.5	0
312	Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology, 2014, 83, 1573-1575.	1.5	90
313	The Role of Diffusion Tensor Imaging in Detecting Microstructural Changes in Prodromal <scp>A</scp>lzheimer's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 3-9.	1.9	55
314	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology, 2014, 83, 1771-1772.	1.5	6
315	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
316	Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurology, 2014, 71, 315.	4.5	48
317	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
318	Association of MAPT haplotypes with Alzheimerâ€™s disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	3.0	106
319	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
320	Chiari 1 Malformation Presenting as Central Sleep Apnea during Pregnancy: A Case Report, Treatment Considerations, and Review of the Literature. Frontiers in Neurology, 2014, 5, 195.	1.1	6
321	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
322	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
323	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
324	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.5	180

#	Article	IF	Citations
325	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
326	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.4	26
327	Concurrent variably protease-sensitive prionopathy and amyotrophic lateral sclerosis. Acta Neuropathologica, 2014, 128, 313-315.	3.9	9
328	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
329	Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2014, 10, 609.	0.4	94
330	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
331	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
332	Genome-wide association interaction analysis for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2436-2443.	1.5	61
333	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49
334	A nonsense mutation in PRNP associated with clinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2656.e13-2656.e16.	1.5	26
335	Evaluation of memory endophenotypes for association with CLU , CR1, and PICALM variants in black and white subjects. , 2014, 10, 205-213.		40
336	Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues. Journal of Alzheimer's Disease, 2014, 42, 1325-1335.	1.2	73
337	ARE PLASMA AÎ² MEASURES ASSOCIATED WITH LONGITUDINAL CHANGE IN HIPPOCAMPAL VOLUME?. , 2014, 10, P270-P271.		0
338	F4-02-03: MULTIMODALITY IMAGING FOR EARLY DIAGNOSIS OF DEMENTIA WITH LEWY BODIES. , 2014, 10, P242-P243.		0
339	Magnetic Resonance Spectroscopy in Common Dementias. Neuroimaging Clinics of North America, 2013, 23, 393-406.	0.5	44
340	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95
341	Focal hemosiderin deposits and Î²â€amyloid load in the ADNI cohort. Alzheimer's and Dementia, 2013, 9, S116-23.	0.4	59
342	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology, 2013, 80, 911-918.	1.5	86

#	Article	IF	Citations
343	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, 770-777.	1.9	62
344	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, spcone-spcone.	1.9	0
345	Early indications of magnetic resonance spectroscopy changes associated with Î²-amyloid load in the cognitively normal. Future Neurology, 2012, 7, 117-118.	0.9	0
346	Cognitive and behavioral features of c9FTD/ALS. Alzheimer's Research and Therapy, 2012, 4, 29.	3.0	20
347	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
348	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
349	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
350	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
351	Magnetic resonance spectroscopy, Î²-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology, 2011, 77, 951-958.	1.5	63
352	Can aerobic exercise protect against dementia?. Alzheimer's Research and Therapy, 2011, 3, 6.	3.0	16
353	Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Medicine, 2011, 12, 445-453.	0.8	236
354	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurology, The, 2011, 10, 785-796.	4.9	733
355	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. American Journal of Neuroradiology, 2010, 31, 1247-1253.	1.2	48
356	IC-01-01: Antemortem PiB binding correlates with postmortem amyloid density in a case with DLB on region of interest analysis. , 2010, 6, S1-S2.		0
357	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
358	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem¹H MR Spectroscopy Metabolite Measurements¹. Radiology, 2008, 248, 210-220.	3.6	147
359	An Extended Analysis of the Histological Variants of Tauâ€Negative FTLD. FASEB Journal, 2008, 22, 58.2.	0.2	0
360	Frontotemporal Dementia. Seminars in Neurology, 2007, 27, 048-057.	0.5	98

#	Article	IF	Citations
361	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1330-1339.	1.5	185
362	Association of Low Plasma AÎ²42/AÎ²40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2007, 64, 354.	4.9	400
363	Normal Pressure Hydrocephalus. Neurologic Clinics, 2007, 25, 809-832.	0.8	44
364	A Cost Effective Method of Identifying and Recruiting Persons Over 80 Free of Dementia or Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2006, 20, 101-104.	0.6	32
365	Magnetic resonance markers for early diagnosis and progression of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2005, 5, 663-670.	1.4	30
366	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. NeuroRx, 2004, 1, 196-205.	6.0	80
367	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. Neurotherapeutics, 2004, 1, 196-205.	2.1	0
368	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
369	1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society, 2002, 8, 934-942.	1.2	109
370	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 198-207.	0.7	135
371	A Cognitive Neuroscience Perspective on Confabulation: Commentary by Neill Graff-Radford (Jacksonville, FL). Neuropsychoanalysis, 2000, 2, 148-150.	0.1	0
372	Mayo's Older Americans Normative Studies: Category Fluency Norms. Journal of Clinical and Experimental Neuropsychology, 1998, 20, 194-200.	0.8	179
373	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.4	2